drugset / Trial / NCT04934696

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

NCT04934696

Phase 1 Completed 25 enrolled Bristol-Myers Squibb
NaSequentialOpen-labelBasic science

Summary

The purpose of this study is to investigate the potential for a drug-drug interaction (DDI) when BMS-986166 and hormonal oral contraceptives are co-administered.

Timeline

Start
2021-08-03
Primary completion
2022-01-25
Completion
2022-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986166 Small molecule
Subject Norethindrone Unknown
Subject ethinyl estradiol Small molecule

Indications

No indication recorded.